NanoVibronix, Inc. (NASDAQ:NAOV) Short Interest Update
by Sarita Garza · The Markets DailyNanoVibronix, Inc. (NASDAQ:NAOV – Get Free Report) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 515,200 shares, a growth of 3,311.9% from the September 30th total of 15,100 shares. Currently, 18.7% of the company’s stock are sold short. Based on an average trading volume of 121,900 shares, the short-interest ratio is presently 4.2 days.
NanoVibronix Trading Up 5.0 %
Shares of NAOV traded up $0.03 during midday trading on Friday, hitting $0.55. 91,317 shares of the company’s stock traded hands, compared to its average volume of 82,782. The stock has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.42 and a beta of 1.50. NanoVibronix has a 1 year low of $0.46 and a 1 year high of $1.55. The firm’s fifty day moving average is $0.60 and its 200-day moving average is $0.69.
NanoVibronix (NASDAQ:NAOV – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. The business had revenue of $0.82 million during the quarter. NanoVibronix had a negative net margin of 83.49% and a negative return on equity of 74.98%.
About NanoVibronix
NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
Featured Stories
- Five stocks we like better than NanoVibronix
- Election Stocks: How Elections Affect the Stock Market
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the NASDAQ Stock Exchange?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Investors Need to Know About Upcoming IPOs
- MarketBeat Week in Review – 10/21- 10/25